A Phase 2 Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder

Trial Profile

A Phase 2 Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2017 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
    • 16 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 25 Jan 2017 Planned initiation date changed from 1 Feb 2017 to 30 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top